CD4CAR for CD4+ Leukemia and Lymphoma

This study is designed as a single arm open label Phase I, 3x3, multicenter study of CD4-directed chimeric antigen receptor engineered T-cells (CD4CAR) in patients with relapsed or refractory T-cell leukemia and lymphoma. Specifically, the study will evaluate the safety and feasibility of CD4CAR T-cells. Funding Source - FDA OOPD

Trial Details

NCT ID
NCT03829540
Phase
PHASE1
Sponsor
Huda Salman
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • CD4CAR
Locations (sample)
  • Miami, Florida, United States|25.77427,-80.19366
  • Indianapolis, Indiana, United States|39.76838,-86.15804
  • Indianapolis, Indiana, United States|39.76838,-86.15804
  • New York, New York, United States|40.71427,-74.00597
  • Stony Brook, New York, United States|40.92565,-73.14094

Key Eligibility Criteria

  • In order to be eligible to participate in this study, an individual will be enrolled if they meet the following criteria:
  • Patients must voluntarily sign and date informed consent forms that state his or her willingness to comply with all study procedures and availabili…
  • Age 12 years old or older
  • Subjects with any documented CD4+ T cell hematologic malignancies. Male and female subjects with CD4+ T-cell hematologic malignancies with either r…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →